Skip to main content
HR 2301 113th Congress House

Clinical Trial Cancer Mission 2020 Act

Official title: To amend the Public Health Service Act to enhance the clinical trial registry data bank reporting requirements and enforcement measures.

Introduced: June 6, 2013 See on congress.gov
Health Drug safety, medical device, and laboratory regulationGovernment information and archivesHealth information and medical recordsHealth programs administration and funding
More subjectsShow fewer subjects
Medical researchMilitary medicine
Sign in to write a letter Sign in to watch
This bill died when the 113th Congress ended
It never became law before the 113th Congress (2013–2014) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 7, 2013
Referred to the Subcommittee on Health.
Jun 6, 2013
Referred to the House Committee on Energy and Commerce.
Jun 6, 2013
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action June 7, 2013

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Clinical Trial Cancer Mission 2020 Act - Revises clinical trial registry data bank provisions of the Public Health Service Act to: (1) include a device or drug clinical trial whether or not it results in a positive or negative outcome, and (2) subject clinical trials funded by the Department of Defense (DOD) to requirements to certify information submissions to the Director of the National Institutes of Health (NIH).

Restricts funding for a grantee and makes the grantee liable to the United States for repayment of any grant amount provided, if the grantee has not submitted clinical trial information within the 30-day correction period for noncompliance.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2301: Clinical Trial Cancer Mission 2020 Act. 113th Congress. Open America. https://openamerica.io/bill/113-HR-2301/
MLA
"H.R. 2301: Clinical Trial Cancer Mission 2020 Act." 113th Congress, 2026, Open America, https://openamerica.io/bill/113-HR-2301/.
Bluebook (legal)
H.R. 2301, 113th Cong. (2026), https://openamerica.io/bill/113-HR-2301/.
Markdown link
[H.R. 2301: Clinical Trial Cancer Mission 2020 Act](https://openamerica.io/bill/113-HR-2301/)
Report a problem